Trending...
- Sonorous Records To Release 8 Albums Of Original Recordings By The Five Blind Boys Of Alabama - 2841
- Avantor® Declares Dividend on Mandatory Convertible Preferred Stock
- New Adjustable Boat Fender Hanger Design Coming in 2021
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) securities between February 2, 2021 and June 10, 2021, inclusive (the "Class Period"). Ocugen investors have until August 16, 2021 to file a lead plaintiff motion.
Investors suffering losses on their Ocugen investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
Ocugen is a biopharmaceutical company. Pursuant to an agreement with Bharat Biotech, Ocugen has the exclusive right to develop, manufacture, and commercialize COVAXIN, a vaccine candidate for COVID-19.
On June 10, 2021, Ocugen announced that it would submit a biologics license application ("BLA") for COVAXIN, which has a longer approval process than an Emergency Use Authorization ("EUA") application, and that it anticipated conducting an additional clinical trial to support the submission.
More on The PennZone
On this news, the Company's share price fell $2.62 per share, or 28%, to close at $6.69 per share on June 10, 2021, thereby injuring investors.
The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the information submitted to the FDA was insufficient to support an EUA, (2) Ocugen would not file an Emergency Use Authorization with the FDA; and (3) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you purchased Ocugen securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Investors suffering losses on their Ocugen investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
Ocugen is a biopharmaceutical company. Pursuant to an agreement with Bharat Biotech, Ocugen has the exclusive right to develop, manufacture, and commercialize COVAXIN, a vaccine candidate for COVID-19.
On June 10, 2021, Ocugen announced that it would submit a biologics license application ("BLA") for COVAXIN, which has a longer approval process than an Emergency Use Authorization ("EUA") application, and that it anticipated conducting an additional clinical trial to support the submission.
More on The PennZone
- Former Isagenix CEO and ConAgra Brands Executive Joins CEO Coaching International®
- Vinco Ventures and ZASH Global Media and Entertainment through their Joint Venture, ZVV Media Partners, Completes Acquisition of Lomotif
- Grovara Co-Founders Abu Kamara and Peter Groverman, Esq., Named to NSBA's Small Business Technology Council To Advocate For High-Tech, Innovative Small Companies
- The South Florida International Film Festival Awards Event for June 2021 Celebrated Filmmakers and Screenwriters
- Exact Solar Named to 2021 List of Top Solar Contractors in North America for 8th Year in a Row
On this news, the Company's share price fell $2.62 per share, or 28%, to close at $6.69 per share on June 10, 2021, thereby injuring investors.
The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the information submitted to the FDA was insufficient to support an EUA, (2) Ocugen would not file an Emergency Use Authorization with the FDA; and (3) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you purchased Ocugen securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Filed Under: Business
0 Comments
Latest on The PennZone
- History Making Footwear Startup, TRONUS Celebrates Super Successful First Year In Business
- Evolve IP Recognized in 2021 Gartner Market Guide for Desktop as a Service for Third Consecutive Year
- Easton Area Orthodontist Offering Affordable Invisalign
- Shareholder Alert: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed Against DraftKings Inc.
- BOUDOIR, an award-winning psychological horror short directed by Gina Lee Ronhovde is now streaming on Bitpix
- Murphy Door CEO Launches NEW Podcast "90 Proof Wisdom with Jeremy G Barker"
- Pennsylvania: Gov. Wolf Visits Wolfgang Confectioners to Announce Expansion Funding and New Jobs at 100-Year-Old York County Food Manufacturer
- Evolve IP Recognized in 2021 Gartner Market Guide for Desktop as a Service for Third Consecutive Year
- JetMax AI Vision Robotic Arm to be launched soon on Kickstarter
- Celebrating America's Favorite Dessert All Month Long
- Sonorous Records To Release 8 Albums Of Original Recordings By The Five Blind Boys Of Alabama
- Storage Made Easy announces SMBStream™, a new product that offers secure accelerated access to SMB Shares over the Internet
- Cogent Infotech Launches a New Website to Streamline Operations and Customer Experience
- PQ Group Holdings Announces Date and Details for Corporate Name Change to Ecovyst Inc. and Second Quarter 2021 Earnings Conference Call
- Markethive Standing Tall In The New Ocean Of Crypto Currencies
- Select Medical Holdings Corporation to Announce Second Quarter 2021 Results on Thursday, August 5
- Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orphazyme A/S (ORPH)
- BEAR Technologies Ranked on Channel Futures MSP 501 for the Second Year in a Row
- Thailand's Finema spearheads decentralized identity tech
- GrooveCar Direct Announces 8 New Credit Union Partnerships in Q2 2021